NCT06837233 - A Study to Assess the Efficacy and Safety of PG-011 Nasal Spray in Adults With Moderate to Severe Seasonal Allergic Rhinitis | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

May 15, 2025

Study Completion Date

May 31, 2026

Conditions

Seasonal Allergic Rhinitis

Interventions

DRUG

Pumecitinib Nasal Spray 0.3%

2 sprays in each nostril, twice daily for 14-day treatment period.

DRUG

Pumecitinib Nasal Spray 0.6%

2 sprays in each nostril, once daily for 14-day treatment period.

DRUG

Placebo (twice daily)

2 sprays in each nostril, twice daily for 14-day treatment period.

DRUG

Pumecitinib nasal spray 0.6%(twice daily)

2 sprays in each nostril, twice daily for 14-day treatment period.

DRUG

Placebo

2 sprays in each nostril, once daily for 14-day treatment period.

Trial Locations (20)

Unknown

Beijing Shijitan Hospital, Capital Medical University, Beijing

Beijing Tongren Hospital, Capital Medical University, Beijing

Beijing Youan Hospital, Capital Medical University, Beijing

Cangzhou Central Hospital, Cangzhou

Hebei Petro China Central Hospital, Langfang

Luo Yang First People's Hospital, Luoyang

Zhengzhou Central Hospital, Zhengzhou

The Central Hospital of Wuhan, Wuhan

Shengjing Hospital of China Medical University, Shenyang

Baotou Central Hospital, Baotou

Chifeng Municipal Hospital, Chifeng

Shandong Second Provincial People's Hospital, Jinan

Liaocheng People's Hospital, Liaocheng

Yantai YuHuangDing Hospital, Yantai

Zibo Central Hospital, Zibo

Linfen Central Hospital, Linfen

Linfen People's Hospital, Linfen

First Hospital of Shanxi Medical University, Taiyuan

The First Affiliated Hospital of Xi'an Jiao Tong University, Xi’an

Yuncheng Central Hospital, Yuncheng